skip to content


GSK and Innoviva report positive COPD results

20 September 2017 08:08

GlaxoSmithKline and Innoviva have announced positive headline results from an IMPACT which showed that single inhaler triple therapy Trelegy Ellipta reduced chronic obstructive pulmonary disease exacerbations.

GSK and Innoviva said Trelegy Ellipta met the study primary endpoint demonstrating a reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD.

Trelegy Ellipta is the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA).

GSK research and development president Patrick Vallance said: 'We are delighted with the positive results achieved in the IMPACT study.

'This is the first study to report a comparison of a single inhaler triple therapy with two dual therapies, providing much needed clinical evidence about the ability of a single inhaler triple therapy to reduce exacerbations.

'It is important to note that all treatments were comprised of different combinations of the same component molecules administered in the same Ellipta inhaler, in a single dose, once a day to allow direct treatment comparisons.

'We hope these results will inform global guidelines and look forward to sharing the results with regulatory authorities.

'We will continue to analyse the wealth of data generated to further the understanding of the treatment of COPD.'

At 8:08am: (LON:GSK) GlaxoSmithKline PLC share price was -2p at 1450p

Story provided by

Related Company: GSK

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.